The use of brincidofovir for the treatment of mixed dsDNA viral infection
详细信息 查看全文
- 作者：Jose F. Camargo ; MDa ; jfc31@med.miami.edu" class="auth_mail" title="E-mail the corresponding author ; josefcamargo@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Michele I. Morrisa ; Lilian M. Abboa ; Jacques Simkinsa ; Seyyedeh Saneeymehrib ; c ; Maritza C. Alencarc ; Lazaros J. Lekakisc ; d ; Krishna V. Komanduric ; d
- 关键词：Brincidofovir ; CMX001 ; Adenovirus ; Cytomegalovirus ; BK virus ; Epstein&ndash ; Barr virus
- 刊名：Journal of Clinical Virology
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：83
- 期：Complete
- 页码：1-4
- 全文大小：333 K
文摘
- •
Brincidofovir (BCV, CMX001) is a novel antiviral but clinical experience is limited.
- •
First report of BCV for treatment of mixed dsDNA viral infection.
- •
BCV resulted in >5 log10 reduction in adenovirus DNA plasma levels.
- •
BCV was safe and effective for the treatment of AdV, CMV, BKV and EBV viremia.